• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Xu Cheryl exercised 2,000 shares at a strike of $0.22, increasing direct ownership by 0.88% to 228,934 units (SEC Form 4)

    5/21/24 8:23:34 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SXTP alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    XU CHERYL

    (Last) (First) (Middle)
    C/O 60 DEGREES PHARMACEUTICALS, INC.
    1025 CONNECTICUT AVENUE NW SUITE 1000

    (Street)
    WASHINGTON DC 20036

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    60 DEGREES PHARMACEUTICALS, INC. [ SXTP ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/16/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock(1) 05/16/2024 M 2,000 A $0.223 228,934 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Stock Unit(2) $0 05/16/2024 M 2,000 (2) (2) Common Stock 2,000 $0 0(2) D
    Explanation of Responses:
    1. This transaction represents the settlement of restricted stock units in shares of common stock on May 16, 2024.
    2. A total of 8,000 restricted stock units ("RSUs") were initially granted to Ms. Xu on July 11, 2023, of which were subsequently modified to 4,000 RSUs and fully vested as of December 31, 2023. Each RSU represents the right to receive, at settlement, one share of common stock.
    /s/ Cheryl Xu 05/21/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SXTP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SXTP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SXTP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • 60 Degrees Pharmaceuticals Announces First Quarter 2025 Results

      Q1 2024 net product revenues increased 55% year-over-year to $163.6 thousand.Gross profit increased 124% to $90.3 thousand. WASHINGTON, May 15, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, reported today their financial results for the first fiscal quarter of the 2025 year, ended March 31, 2025. Financial Highlights for the Quarter Ended March 31, 2025: Net product revenues increased approximately 55% from $105.7 thousand for the first quarter of 2024 to approximately $163.6 thousand for the first quarter of 2025; the Company credits growth from domes

      5/15/25 4:31:00 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21

      WASHINGTON, April 10, 2025 (GLOBE NEWSWIRE) -- Geoff Dow, infectious disease product development expert and chief executive officer of 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees" or the "Company"), will participate in a scientific discussion on the management and treatment of babesiosis during the April 15–21 Healing Lyme Summit. Babesiosis is a rapidly emerging tick-borne disease often found as a coinfection with Lyme disease. Drawing on decades of experience in anti-infective product development, Dr. Dow will spotlight the growing threat of babesiosis in the United States, its clinical challenges, and the urgent need for increased awareness and improved diagnos

      4/10/25 8:31:00 AM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health

      WASHINGTON, D.C., April 08, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees" or the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced the signing of a Patent License Agreement with Yale School of Medicine and Yale School of Public Health to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. Tafenoquine is not currently approved by the U.S. Food and Drug Administration ("FDA") for the treatment and prevention of babesiosis. The agreement follows initiation of collaboration between researchers from both organizations

      4/8/25 8:31:00 AM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SXTP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Xu Cheryl bought $21,400 worth of shares (13,000 units at $1.65), increasing direct ownership by 32% to 54,078 units (SEC Form 4)

      4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

      12/18/24 8:35:59 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Dow Geoffrey S bought $89,755 worth of shares (73,951 units at $1.21), increasing direct ownership by 358% to 94,580 units (SEC Form 4)

      4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

      12/9/24 5:07:49 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Dow Geoffrey S bought $6,367 worth of shares (7,000 units at $0.91), increasing direct ownership by 51% to 20,629 units (SEC Form 4)

      4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

      11/21/24 6:14:45 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SXTP
    Financials

    Live finance-specific insights

    See more
    • VSee Health and 60 Degrees Pharmaceuticals Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / December 2, 2024 / RedChip Companies aired interviews with VSee Health, Inc. (NASDAQ:VSEE) and 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV on November 30. Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:VSEE: https://www.redchip.com/assets/access/vsee_accessSXTP: https://www.redchip.com/assets/access/sxtp_accessIn an exclusive interview, Imo Aisiku, M.D., co-CEO and Chairman of VSee Health, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to share insight into how VSee Health's differentiated so

      12/2/24 4:05:00 PM ET
      $SXTP
      $VSEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Nursing Services
    • 60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / November 22, 2024 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) and Can-Fite BioPharma Ltd. (NYSE:CANF)(TASE:CANF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, November 23, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:SXTP: https://www.redchip.com/assets/access/sxtp_accessCANF: https://www.redchip.com/assets/access/canf_accessIn an exclusive interview, Geoffrey Dow, CEO and President of 60 Degrees Pharmaceuticals, appears on the RedChip Small Stocks Big Money™ show on

      11/22/24 9:00:00 AM ET
      $CANF
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genetic Technologies Limited and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Money Report® on Bloomberg TV

      MELBOURNE, Australia, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in guideline driven genomics-based tests in health, wellness and serious disease is pleased to advise that RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and 60 Degrees Pharmaceuticals (60P) (NASDAQ:SXTP) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 2, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S. Access the interviews in their entirety at: •  Genetic Technologies (NASDAQ:GENE): https://www.redchip.com/

      9/1/23 10:00:00 AM ET
      $GENE
      $SXTP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $SXTP
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by 60 Degrees Pharmaceuticals Inc.

      SCHEDULE 13G/A - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)

      5/15/25 3:10:40 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by 60 Degrees Pharmaceuticals Inc.

      10-Q - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

      5/15/25 10:07:28 AM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by 60 Degrees Pharmaceuticals Inc.

      SCHEDULE 13G - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)

      5/14/25 2:57:24 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SXTP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by President and CEO Dow Geoffrey S

      4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

      1/24/25 4:52:30 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CFO Miller Tyrone

      4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

      1/24/25 4:51:10 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Dow Geoffrey S was granted 14,394 shares, increasing direct ownership by 15% to 108,974 units (SEC Form 4)

      4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

      1/21/25 5:00:27 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SXTP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by 60 Degrees Pharmaceuticals Inc.

      SC 13G - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)

      11/14/24 3:37:18 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by 60 Degrees Pharmaceuticals Inc.

      SC 13G/A - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)

      11/13/24 4:01:15 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by 60 Degrees Pharmaceuticals Inc. (Amendment)

      SC 13G/A - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)

      5/7/24 7:19:08 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care